Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atreca, Inc.BCEL · Entity 91940 | Chief Financial Officer | August 02, 2023 | August 04, 2023 |
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Chief Financial Officer | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atreca, Inc.
Report date August 02, 2023 · Filed August 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 72,817 |
Reported balance
After 2023-08-02 transaction · row 1
1 source rowRow 1 · 2023-08-02 · Sale · Disposed 5,487 · Balance 72,817 F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" and does not represent a discretionary trade by the Reporting Person. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $0.97 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" and does not represent a discretionary trade by the Reporting Person.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $0.97 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Jasper Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.84 · Expires 2036-01-02 | Direct | 90,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 90,000 · Balance 90,000 F1: 1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARMO BioSciences, Inc.
Report date June 22, 2018 · Filed June 22, 2018
Section 16 reporting ended · disclosed 2018-06-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.97 · Expires 2027-12-12 | Direct | 0 |
Reported balance
After 2018-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-22 · Disposition to issuer · Disposed 240,658 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in forty-eight equal monthly installments following November 27, 2017, subject to a one-year cliff, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.
F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
F3: This option, which provided for vesting in forty-eight equal monthly installments following November 27, 2017, subject to a one-year cliff, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Apexigen, Inc.
Report date August 23, 2023 · Filed August 25, 2023
Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.94 · Expires 2029-11-08 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 34,084 · Balance 0 F1: The shares subject to the option vest in 48 equal monthly installments beginning on November 3, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2032-09-29 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-23 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in 48 equal monthly installments beginning on November 3, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
F2: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 19:30 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001213900-26-001382 · ownership.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Voting Common Stock · 90,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on January 2, 2027, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 06:25 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001213900-25-051724 · ownership.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Voting Common Stock · 90,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: 1/4th of the shares subject to the retention option shall vest on June 4, 2026 and 1/48th of the shares subject to the retention option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:30 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001213900-25-014949 · ownership.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Voting Common Stock · 50,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 13, 2026, and 1/48th of the original number of shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 19:27 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001213900-24-015459 · ownership.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Voting Common Stock · 40,000 shares Expires 2034-02-15 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 15, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 16:16 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 550,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001213900-23-079569 · ownership.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,000 Underlying: Voting Common Stock · 550,000 shares Expires 2033-09-22 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on September 22, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:24 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $2.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-047444 · doc4.xml · derivative · entry 2 CROSS HERB · CIK 0001230721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F2 · price: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F2 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:24 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 34,084 | Not disclosed Strike: $6.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-047444 · doc4.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,084 shares Expires 2029-11-08 F1 · price: The shares subject to the option vest in 48 equal monthly installments beginning on November 3, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on November 3, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 18:55 UTC | Atreca, Inc. BCEL · Entity 91940 | SaleClass A Common Stock | 5,487 | $0.95 | $5,224.72 |
DisclosureSEC source: 0001209191-23-044684 · doc4.xml · nonDerivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,817 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $0.97 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 20:58 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantEmployee stock option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001209191-23-008957 · doc4.xml · derivative · entry 2 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Class A Common Stock · 175,000 shares Expires 2033-02-08 F2 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from January 1, 2023. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 20:58 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantClass A Common Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008957 · doc4.xml · nonDerivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,304 F1 · shares: The reporting person received an award of 43,750 restricted stock units on February 9, 2023, vesting in three equal annual installments beginning on August 1, 2023. Each restricted stock unit represents a right to receive one share of Atreca Class A Common Stock upon vesting. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 17:57 UTC | Apexigen, Inc. APGN · Entity 110214 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001209191-22-051929 · doc4.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Read SEC document |
| September 02, 2022 Filed Sep 20, 2022 18:11 UTC | Atreca, Inc. BCEL · Entity 91940 | SaleClass A Common Stock | 7,646 | $1.78 | $13,573.18 |
DisclosureSEC source: 0001209191-22-050777 · doc4.xml · nonDerivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,554 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" and does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.83 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 19:14 UTC | Atreca, Inc. BCEL · Entity 91940 | Disposition to issuerEmployee stock option (right to buy) · Derivative | 97,000 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001209191-22-037111 · doc4.xml · derivative · entry 6 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 97,000 shares Expires 2030-02-25 F4 · derivative.exercise_date: 2/48 of the Option vests on 3/1/2020 and 1/48 of the Option vests in equal monthly installments as measured from 3/1/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 19:14 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantEmployee stock option (right to buy) · Derivative | 97,000 | Not disclosed Strike: $1.85 | Not disclosed |
DisclosureSEC source: 0001209191-22-037111 · doc4.xml · derivative · entry 5 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,000 Underlying: Class A Common Stock · 97,000 shares Expires 2030-02-25 F2 · price: The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the "Option Repricing"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022. Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option. The Option Repricing does not apply to options held by non-employee directors of the Issuer. F4 · derivative.exercise_date: 2/48 of the Option vests on 3/1/2020 and 1/48 of the Option vests in equal monthly installments as measured from 3/1/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 19:14 UTC | Atreca, Inc. BCEL · Entity 91940 | Disposition to issuerEmployee stock o16.74ption (right to buy) · Derivative | 224,999 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001209191-22-037111 · doc4.xml · derivative · entry 4 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 224,999 shares Expires 2029-04-04 F3 · derivative.exercise_date: 1/4 of the Option vests on 2/25/2020 and 1/48 of the Option vests in equal monthly installments as measured from 2/25/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 19:14 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantEmployee stock option (right to buy) · Derivative | 224,999 | Not disclosed Strike: $1.85 | Not disclosed |
DisclosureSEC source: 0001209191-22-037111 · doc4.xml · derivative · entry 3 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,999 Underlying: Class A Common Stock · 224,999 shares Expires 2029-04-04 F2 · price: The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the "Option Repricing"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022. Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option. The Option Repricing does not apply to options held by non-employee directors of the Issuer. F3 · derivative.exercise_date: 1/4 of the Option vests on 2/25/2020 and 1/48 of the Option vests in equal monthly installments as measured from 2/25/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 19:14 UTC | Atreca, Inc. BCEL · Entity 91940 | Disposition to issuerEmployee stock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $13.97 | $0.00 |
DisclosureSEC source: 0001209191-22-037111 · doc4.xml · derivative · entry 2 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 95,000 shares Expires 2031-01-26 F1 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 19:14 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantEmployee stock option (right to buy) · Derivative | 95,000 | Not disclosed Strike: $1.85 | Not disclosed |
DisclosureSEC source: 0001209191-22-037111 · doc4.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Class A Common Stock · 95,000 shares Expires 2031-01-26 F2 · price: The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the "Option Repricing"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022. Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option. The Option Repricing does not apply to options held by non-employee directors of the Issuer. F1 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 18:51 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantEmployee stock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001209191-21-071426 · doc4.xml · derivative · entry 2 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Class A Common Stock · 95,000 shares Expires 2031-12-22 F1 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 12/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Early Exercise is not permitted. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 21:45 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantClass A Common Stock | 42,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-055808 · doc4.xml · nonDerivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,200 F1 · shares: The shares of common stock are to be acquired upon the vesting of a restricted stock unit award granted to the Reporting Person. The restricted stock unit award shall vest as follows: vest over two years (vesting commencement date = September 1, 2021), with a one-year cliff as follows: on the first anniversary of the vesting commencement date, 50% of the restricted stock unit award shall vest, and on the second anniversary of the vesting commencement date, 50% of the restricted stock unit award shall vest. In total, 100% of the restricted stock unit award shall be vested on the second anniversary of the vesting commencement date. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 20:26 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantEmployee stock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $13.97 | $0.00 |
DisclosureSEC source: 0001209191-21-006336 · doc4.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Class A Common Stock · 95,000 shares Expires 2031-01-26 F1 · derivative.exercise_date: 1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 17:29 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantEmployee stock opiton (right to buy) · Derivative | 97,000 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001209191-20-014069 · doc4.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,000 Underlying: Class A Common Stock · 97,000 shares Expires 2030-02-25 F1 · derivative.exercise_date: 2/48 of the Option vests on 3/1/2020 and 1/48 of the Option vests in equal monthly installments as measured from 3/1/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time. Read SEC document |
| June 22, 2018 Filed Jun 22, 2018 17:13 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | Disposition to issuerStock Option (right to buy) · Derivative | 240,658 | $43.03 Strike: $6.97 | $10,355,561.87 |
DisclosureSEC source: 0000899243-18-017716 · doc4.xml · derivative · entry 1 CROSS HERB · CIK 0001230721 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,658 shares Expires 2027-12-12 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3 · derivative.exercise_date: This option, which provided for vesting in forty-eight equal monthly installments following November 27, 2017, subject to a one-year cliff, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.